Stereotactic body radiotherapy: Prospective study to evaluate asthenia and quality of life.

[Stereotactic body radiotherapy: Prospective study to evaluate asthenia and quality of life]. Cancer Radiother. 2019 May 29;: Authors: Abbassi LM, Laurans M, Gasnier A, Smulevici A, Tournat H, Bibault JE, Huertas A, Jouglar E, Suissa A, Kreps S, Giraud P, Durdux C Abstract PURPOSE: To evaluate prospectively asthenia and the quality of life in patients treated by stereotactic body irradiation and to determine their predictive factors. METHODS AND MATERIALS: Quality of life was assessed by the EORTC QLQ-C30 and asthenia was evaluated with the Brief Fatigue Inventory (BFI), on the first day (T1), last day (T2) and 1-3 weeks after the end of treatment (T3). RESULTS: Sixty-three patients were treated with stereotactic body irradiation from February 2017 to May 2017 and 41 were included in the analysis (22 patients excluded for lack of understanding, organization, psychologic disorders or refusal). The mean number of fractions was 5 (±2). The compliance to quality of life assessment was 98%, 95% was 81% at T1, T2 and T3, respectively. An increase of asthenia and a worsened quality of life were found in 12 (29%) and 14 (34%) patients between T1 and T2. Univariate analysis demonstrated a correlation between asthenia and quality of life were correlated with performans status (P=0.03 and 0.05 respectively), hemoglobin level (p=0.01 and 0.004), albumin level (P=0.01 and 0.06), distance between home and radiotherapy department (P=0.05 and 0.02). Mul...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research

Related Links:

Publication date: Available online 20 August 2019Source: European UrologyAuthor(s): Marko Babjuk, Maximilian Burger, Eva M. Compérat, Paolo Gontero, A. Hugh Mostafid, Joan Palou, Bas W.G. van Rhijn, Morgan Rouprêt, Shahrokh F. Shariat, Richard Sylvester, Richard Zigeuner, Otakar Capoun, Daniel Cohen, José Luis Dominguez Escrig, Virginia Hernández, Benoit Peyronnet, Thomas Seisen, Viktor SoukupAbstractContextThis overview presents the updated European Association of Urology (EAU) guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ (CIS).ObjectiveTo provide ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: Patients undergoing surgery for PCL have high rates of margin positivity and high short-term mortality. Chemotherapy improves survival, but
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: J Surg Oncol Source Type: research
In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 20 August 2019Source: Pharmacological ResearchAuthor(s): Hong-Yuan Lu, Yu-Xin Zu, Xiao-Wen Jiang, Xiao-Tong Sun, Tian-Yi Liu, Ruo-Lan Li, Qiong Wu, Ying-Shi Zhang, Qing-Chun ZhaoAbstractAcquired drug-resistant non-small cell lung cancer (NSCLC) has strong proliferation ability and is prone to epithelial-mesenchymal transition (EMT) and subsequent metastasis. Notch pathway mediates cell survival and EMT and is involved in the induction of multidrug resistance (MDR). ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 we found before. However, the effects of ZLDI-8 on resista...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Merkel cell carcinoma is an aggressive neuroendocrine skin cancer with high morbidity and mortality. In addition to gene mutations and UV-induced damage, the Merkel cell polyomavirus (MCPyV) has been identified as a key driver of Merkel cell carcinogenesis. While UV-mediated DNA damage is known to contribute to MCC pathogenesis via TP53 mutations and reduced expression of DNA damage recognition proteins, the role of MCPyV in the DNA damage response (DDR) pathway remains unknown. Given that measurement of DDR has clinical value in assessing treatment response to radio- and chemotherapy, we sought to investigate whether MCPy...
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer after basal cell carcinoma. While most cases are cured by excision, a substantial number of patients will develop local, regional, or distant recurrences, with the number of cSCC-related deaths approaching that from melanoma. Several clinical decisions, including the extent of surgical margins, the use of adjuvant radiation or chemotherapy, and sentinel lymph node biopsy/completion dissection, could be informed by a patient ’s relative risk of recurrence.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
We report the development of hidradenitis suppurativa (HS) in a patient after initiation of treatment with sorafenib. To our knowledge, sorafenib-induced HS in the axillary and inguinal skin folds has not been previously reported. A 33-year-old male on sorafenib for papillary thyroid cancer presented for evaluation of “boils” that began when he initiated chemotherapy 5 years prior and had continued to progress.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Case Description: A 67-year-old male with history of adenosquamous prostate cancer status post prostatectomy, cystectomy, diverting loop colostomy with urostomy, leuprolide, and radiation was recently started on chemotherapy with docetaxel. He presented to emergency room 3 days after his first docetaxel infusion with complains of fever, nausea, and skin rash in bilateral axillae, and arms. The rash was mildly pruritic and painful. The patient had a recent episode of mild sunburn a week prior to his infusion, which had completely resolved before infusion.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Condition:   Epithelial Ovarian Cancer Intervention:   Drug: adjuvant chemotherapy Sponsors:   Japanese Gynecologic Oncology Group;   Korean Gynecologic Oncology Group Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Psychology | Science | Study